BioCentury | Oct 2, 2019
Financial News

Three new IPO filings broaden fall queue

...cell-mediated autoimmune diseases. The company intends to begin its first clinical study next year of DSG3-CAART...
BioCentury | Jan 4, 2019
Financial News

Venture roundup: Cabaletta, Thousand Oaks, Sojournix

...3. Cabaletta intends to use its $50M series B funding to bring its lead product, DSG3-CAART...
...Cabaletta Bio Inc., Radnor, Pa. Sojournix Inc., Waltham, Mass. Thousand Oaks Biopharmaceuticals Inc., Haimen, China Sandi Wong DSG3-CAART SJX-653 Cabaletta...
BioCentury | Jan 3, 2019
Financial News

Venture roundup: Cabaletta, Thousand Oaks, Sojournix

...Thursday. Cabaletta intends to use its $50M series B funding to bring its lead product, DSG3-CAART...
...with $31M, Ipsen Compounds" ). DSG3 - Desmoglein 3; NK3R (TACR3) - Neurokinin 3 receptor Sandi Wong DSG3-CAART Cabaletta...
BioCentury | Nov 9, 2018
Financial News

Cabaletta spins out of Penn with CAR T autoimmune therapy, $38M series A

...of self-reactive B cells by expressing the autoantigen on the cell surface. Cabaletta's lead product, DSG3-CAART...
...pemphigus vulgaris. A study led by Payne and published in 2016 in Science showed that DSG3-CAART...
...to complete a first-in-human trial of DSG3-CAART. He expects Cabaletta to submit an IND for DSG3-CAART...
BioCentury | Nov 8, 2018
Financial News

Cabaletta spins out of Penn with CAR T autoimmune therapy, $38M series A

...of self-reactive B cells by expressing the autoantigen on the cell surface. Cabaletta's lead product, DSG3-CAART...
...pemphigus vulgaris. A study led by Payne and published in 2016 in Science showed that DSG3-CAART...
...to complete a first-in-human trial of DSG3-CAART. He expects Cabaletta to submit an IND for DSG3-CAART...
Items per page:
1 - 5 of 5